STAAR Surgical Company
Financials
Valuation Metrics
STAAR Surgical Company's Market Cap is $1.04B. At end of 2025 it was $1.14B. Ranked #2446 of 3,121 in US market (top 78%), #995 of 1,463 on NASDAQ (top 68%), #154 of 205 in Health Care Equipment & Services (top 75%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.04B | US#2,446/3,121 Sec#154/205 |
| Revenue | $340M | US#2,409/3,121 Sec#152/205 |
| Net Income | $4M | US#2,215/3,121 Sec#117/205 |
| Total Assets | $475M | US#2,787/3,121 Sec#161/205 |
| Net Assets | $365M | US#2,434/3,121 Sec#133/205 |
| Employees | 921 | US#2,020/3,121 Sec#138/205 |
| Value | ||
| P/E | 270.02x | US#2,196/3,121 Sec#114/205 |
| P/B | 2.84x | US#1,710/3,121 Sec#92/205 |
| P/S | 3.05x | US#1,748/3,121 Sec#118/205 |
| EV/EBITDA | 28.83x | US#2,203/3,121 Sec#117/205 |
| FCF Yield | -0.65% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | 1.05% | US#2,091/3,121 Sec#111/205 |
| ROA | 0.81% | US#2,057/3,121 Sec#115/205 |
| Op. Margin | 10.32% | US#1,572/3,121 Sec#74/205 |
| Revenue Growth | 51.30% | US#219/3,121 Sec#11/205 |
| Financial Health | ||
| Debt Ratio | 30.05% | US#337/3,121 Sec#36/205 |
| Total Debt | $36M | US#2,671/3,121 Sec#158/205 |
| FCF | $-7M | US#2,362/3,121 Sec#149/205 |
| Cash | $149M | US#1,961/3,121 Sec#121/205 |
| Current Ratio | 4.66x | US#514/3,121 Sec#44/205 |
| Net Debt/EBITDA | -3.51x | US#95/3,121 Sec#10/205 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/205 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | -23.34% | US#2,441/3,121 Sec#165/205 |
| 1M Return | -15.57% | US#2,746/3,121 Sec#185/205 |
| From 52W High | -41.96% | US#2,481/3,121 Sec#166/205 |
| 1Y MDD | -42.66% | US#2,145/3,121 Sec#126/205 |
| Trading | ||
| Volume | 4,748,650 shares | US#1,628/3,121 Sec#103/205 |
| Trading Value | $99M | US#2,007/3,121 Sec#136/205 |
| Per Share | ||
| EPS | $0.08 | US#2,102/3,121 Sec#115/205 |
| BPS | $7.34 | US#2,056/3,121 Sec#120/205 |
Company Info
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.